Key facts
- It has raised $17.4M.
- Notable investors include Mitsubishi UFJ Capital, J-Startup, JIC Venture Growth Investments, Intellectual Property Acceleration Program for Startups, Kyoto University Innovation Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Toregem Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Toregem Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Toregem Biopharma
Developer of therapeutic agents designed for dental regenerative medicines. The company offers investigational antibody drugs targeting rare congenital conditions such as severe congenital oligodontia with drug development efforts to provide new treatment options for patients lacking permanent teeth or suffering from intraoral frailty, enabling medical professionals and patients within the dental and oral healthcare markets to access potentially curative therapies.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2020
- Employees
- 5
- Website
- toregem.co.jp/
- Ownership
- Privately Held (backing)
Toregem Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Toregem Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Toregem Biopharma in its N-PORT filings yet. We sweep new filings monthly.